KRAS and metastatic neoplasm: However, KRAS mutant metastatic tumor showed poorer survival versus their KRAS wild-type counterparts (P=4.285 × 10−6), further suggesting the importance of KRAS mutation detection in the clinical management of metastatic tumors.